Iulia Cristina Tudor

Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design.

Jorge Plutzky, DIANNE CHEUNG, Elena A. Christofides, Iulia Cristina Tudor et autres

Hypertension is a leading modifiable risk factor for cardiovascular disease and premature death among adults. Up to 18% of individuals with hypertension have resistant hypertension (rHTN), which substantially increases the risk of adverse clinical outcomes. Endogenous hypercortisolism can result in rHTN through …

us (code pays fourni par la source)

Real-world comparative effectiveness of nab-paclitaxel and paclitaxel in combination with bevacizumab in patients with platinum-resistant ovarian cancer (COMPASS)

Robert Coleman, Raina Mathur, Anju Parthan, Prakirthi Yerram et autres

us (code pays fourni par la source)

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial

Domenica Lorusso, Laurence Gladieff, David M O'Malley, Jae-Weon Kim et autres

BACKGROUND: Relacorilant is a selective glucocorticoid receptor antagonist that increases the sensitivity of many cancer cell types to chemotherapy. The efficacy and safety of relacorilant plus nab-paclitaxel were assessed in the phase 3 ROSELLA (GOG-3073, ENGOT-ov72, APGOT-Ov10, and LACOG-0223) trial; the combination …

it, fr, us, kr, ar, ca, au, es, br, gb, hu, be (code pays fourni par la source)

Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study

Rosario Pivonello, Rosario Pivonello, Giorgio Arnaldi, Richard J Auchus et autres

it, es, us, ro, de, bg, nl, pl (code pays fourni par la source)

Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension

Jorge Plutzky, Pam R. Taub, Deepak L. Bhatt, Omar Al Dhaybi et autres

BACKGROUND: Hypertension is a leading modifiable risk factor for cardiovascular disease and premature death among adults. Up to 18% of individuals with hypertension have resistant hypertension (rHTN), which substantially increases the risk of adverse clinical outcomes. Endogenous hypercortisolism can result in rHTN …

us (code pays fourni par la source)

Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)

Mark S. Shahin, Raina Mathur, Anju Parthan, Prakirthi Yerram et autres

OBJECTIVE: To compare the real-world effectiveness and safety of monotherapy nab-paclitaxel and paclitaxel in patients with platinum-resistant ovarian cancer (PROC). METHODS: COMPASS is a retrospective, observational study using deidentified patient data from the longitudinal US Flatiron Health Research Database in patients with …

us (code pays fourni par la source)

Corrigendum to “Medical treatment of hypercortisolism with relacorilant: Final results of the phase 3 GRACE study” [American Heart Journal 278S (2024) Pages 10-11]

Rosario Pivonello, Giorgio Arnaldi, Richard Joseph Auchus, Corin Badiu et autres

Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial

Alexander Babatunde Olawaiye, Laurence Gladieff, David M. O’Malley, Jae‐Weon Kim et autres

(Abstracted from Lancet 2025;405(10496):2205–2216) Deaths related to ovarian cancer were estimated at 207,000 in 2020 across the globe. An approximate 70% of patients have relapses of the disease after platinum-based chemotherapy as they develop resistance to the treatment; platinum-resistant ovarian cancer can …

MON-572 Characterization of Individuals With Difficult-to-Control Type 2 Diabetes and Post-Dexamethasone Suppression Test Cortisol Values <1.2, 1.2-1.8, and >1.8 µg/dL: Findings From the CATALYST Part 1 Study

Richard Joseph Auchus, Timothy Silleck Bailey, Lawrence Blonde, Robert S. Busch et autres

Abstract Disclosure: R.J. Auchus: Neurocrine Biosciences/Neurocrine UK, LTD, Spruce Biosciences, Corcept Therapeutics, Crinetics Pharmaceuticals, Recordati Rare Diseases, Adrenas Therapeutics, Mineralys Pharmaceuticals, Quest Diagnostics, Xeris Pharmaceuticals, Novo Nordisk, H Lundbeck A/S, Sparrow Pharmaceuticals, Astellas Pharmaceuticals, Acerand Therapeutics. T. Bailey: Abbott Rapid Diagnostics, Biolinq, …

us, gb (code pays fourni par la source)

MON-302 The Design of MOMENTUM: A Prospective Study of the Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension

Jorge Plutzky, Richard Joseph Auchus, JAN N. BASILE, Deepak L. Bhatt et autres

Abstract Disclosure: J. Plutzky: Altimmune, Amgen Inc, Boehringer Ingelheim, Corcept Therapeutics, New Amsterdam, Novo Nordisk, Toku Eyes, Esperion, Novartis Pharmaceuticals. R.J. Auchus: Neurocrine Biosciences/Neurocrine UK, LTD, Spruce Biosciences, Corcept Therapeutics, Crinetics Pharmaceuticals, Recordati Rare Diseases, Adrenas Therapeutics, Mineralys Therapeutics, Quest Diagnostics, Xeris …

us (code pays fourni par la source)

High Medication Burden in Individuals With Difficult-to-Control Type 2 Diabetes: Clinical Characteristics From the CATALYST Study

Ralph Anthony DeFronzo, John B. Buse, Bradley Eilerman, Vivian Andrew Fonseca et autres

us (code pays fourni par la source)

The Design of MOMENTUM: A Prospective Study of the Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension

Jorge Plutzky, Richard Joseph Auchus, Jan Basile, Deepak L. Bhatt et autres

us (code pays fourni par la source)